Review of "angiotensin genotype, sodium reduction, weight loss, and prevention of hypertension: Trials of hypertension prevention, phase II"

Current Hypertension Reports

Volumn 1, Issue 1, 1999, Pages 13-14

  Schork, Nicholas J ^a,b,c  

^a METROHEALTH MEDICAL CENTER   (United States)

^b HARVARD UNIVERSITY   (United States)

^c JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN DERIVATIVE; ANGIOTENSINOGEN;

ADULT; ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; GENETICS; GENOTYPE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SODIUM RESTRICTION; WEIGHT REDUCTION;

ADULT; ALLELES; ANGIOTENSINOGEN; ANGIOTENSINS; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; DIET, SODIUM-RESTRICTED; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; WEIGHT LOSS;

EID: 0033068862     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-999-0068-8     Document Type: Review

References (11)

1. Schork NJ, Weder AB: The use of genetic information in largescale clinical trials: applications to Alzheimer's disease. Alz Dis Assoc Disord 1996, 10:22-26.
2. Ball S, Borman N: Pharmacogenetics and drug metabolism. Nature Biotechnol 1997, 15:925-926.
3. Marshall A: Getting the right drug into the right patient. Nature Biotechnol 1997, 15:1249 1252.
4. Marshall A: Laying the foundations for personalized medicines. Nature Biotechnol 1997, 15:954-959.
5. Nebert DW, Weber WW: Pharmacogenetics. In Principles of Drug Action. Edited by Pratt WB, Taylor P. New York: Churchill Livingstone; 1990.
6. Hunt SC, Cook NR, Oberman A, et al.: Angiotensin genotype, sodium retention, weight loss, and prevention of hypertension: trials of hypertension prevention, Phase II. Hypertension 1998, 32:393-401.
7. Trials of Hypertension Prevention CRG: The hypertension prevention trial: three-year effects of dietary changes on blood pressure. Arch Intern Med 1990, 150:153-162. (Pubitemid 20085215)
8. Trials of Hypertension Prevention CRG: The effects of nonpharmacologic interventions on blood pressure of persons with high-normal levels: results of the Trials of Hypertension, Phase I. JAMA 1992, 267:1213-1220.
9. Trials of Hypertension Prevention CRG: Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in over-weight people with high-normal blood pressure: the Trials of Hypertension Prevention. Arch Intern Med 1997, 157:657-667. (Pubitemid 27133196)
10. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al.: Molecular basis of human hypertension: role of angiotensinogen. Cell 1992, 71:169-180.
11. Lifton RP: Molecular genetics of human blood pressure variation. Science 1996, 272:676-680. (Pubitemid 26000271)